% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Olma:275876,
      author       = {Olma, Manuel C and Steindorf-Sabath, Lena and Tütüncü,
                      Serdar and Kunze, Claudia and Fiessler, Cornelia and
                      Kirchhof, Paulus and Dietzel, Joanna and Schurig, Johannes
                      and Oschmann, Patrick and Niehaus, Ludwig and Urbanek,
                      Christian and Thomalla, Götz and Nabavi, Darius G and
                      Röther, Joachim and Laufs, Ulrich and Veltkamp, Roland and
                      Heuschmann, Peter U and Haeusler, Karl Georg and Endres,
                      Matthias},
      collaboration = {Investigators, MonDAFIS},
      title        = {{T}he {R}ole of {A}trial {F}ibrillation and {O}ral
                      {A}nticoagulation {S}tatus in {H}ealth-{R}elated {Q}uality
                      of {L}ife 12 {M}onths {A}fter {I}schemic {S}troke or {TIA}.},
      journal      = {Brain and behavior},
      volume       = {15},
      number       = {1},
      issn         = {2162-3279},
      address      = {Malden, Mass.},
      publisher    = {Wiley},
      reportid     = {DZNE-2025-00111},
      pages        = {e70248},
      year         = {2025},
      abstract     = {Atrial fibrillation (AF) accounts for about $20\%$ of all
                      ischemic strokes worldwide. It is known that AF impairs
                      health-related quality of life (HRQOL) in the general
                      population, but data on HRQOL in stroke patients with newly
                      diagnosed AF are sparse.Post hoc analysis of the
                      prospective, investigator-initiated, multicenter MonDAFIS
                      study (NCT02204267) to analyze whether AF-related oral
                      anticoagulation (OAC), and/or AF-symptom severity are
                      associated with HRQOL after ischemic stroke or transient
                      ischemic attack (TIA). HRQOL was measured using the
                      EQ-5D-3L-questionnaire (including EQ-index/EQ-VAS) at
                      baseline and after 12 months using multivariable linear
                      mixed models. AF symptom severity was assessed using the
                      European Heart Rhythm Association classification and symptom
                      severity score (EHRA score) categorizing patients with
                      no/mild/severe/disabling AF-related symptoms.A first episode
                      of AF was detected in 261/2927 $(8.9\%)$ patients within 12
                      months after the index stroke and 227/2920 $(7.8\%)$
                      patients had AF and were anticoagulated at 12 months. HRQOL
                      (measured by EQ-index, n = 2495 patients) was higher in AF
                      patients on OAC compared to AF patients without OAC at 12
                      months after stroke (mean difference: MD: -16.8, $95\%$ CI:
                      5.6 to 28.0), and similar in AF patients under OAC compared
                      with patients without AF (MD: 2.0, $95\%$ CI: -2.2 to 6.3).
                      AF-related symptoms were negatively associated with HRQOL
                      (measured by EQ-index) indicating that stroke patients with
                      AF-related symptoms had a lower HRQOL compared to
                      asymptomatic AF patients (mild vs. asymptomatic: MD: -9.0,
                      $95\%$ CI: -17.7 to -0.3; severe/disabling vs. asymptomatic:
                      MD: -19.1, $95\%$ CI: -34.7 to -3.4).Stroke patients with
                      newly diagnosed AF are at risk of lower quality of life at
                      12 months, depending on OAC status and AF symptom severity.},
      keywords     = {Humans / Atrial Fibrillation: drug therapy / Atrial
                      Fibrillation: physiopathology / Atrial Fibrillation:
                      complications / Quality of Life / Female / Male /
                      Anticoagulants: administration $\&$ dosage / Aged / Ischemic
                      Stroke: physiopathology / Ischemic Attack, Transient:
                      physiopathology / Middle Aged / Prospective Studies / Aged,
                      80 and over / Administration, Oral / Severity of Illness
                      Index / atrial fibrillation (Other) / ischemic stroke
                      (Other) / oral anticoagulation (Other) / quality of life
                      (Other) / transient ischemic attack (Other) / Anticoagulants
                      (NLM Chemicals)},
      cin          = {AG Endres},
      ddc          = {610},
      cid          = {I:(DE-2719)1811005},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39779216},
      pmc          = {pmc:PMC11710889},
      doi          = {10.1002/brb3.70248},
      url          = {https://pub.dzne.de/record/275876},
}